Table 2.
Treatment characteristics of node-positive patients (n = 447)
| Characteristic | N+ (n = 447) | 1 pos LN (n = 172) | 2 pos LN (n = 102) | 3 pos LN (n = 62) | >3 pos LN (n = 87) | Unknown number of positive LNs (n = 24) |
|---|---|---|---|---|---|---|
| No Tx | ||||||
| Number of pts | 169 (37.8%) | 86 (50.0%) | 34 (33.3%) | 18 (29.0%) | 25 (28.7%) | 6 (25.0%) |
| Neoadjuvant Tx | ||||||
| Number of pts | 3 (0.7%) | 1 (0.6%) | 1 (1.0%) | 1 (1.6%) | 0 | 0 |
| Unknown Tx | ||||||
| Number of pts | 31 (6.9%) | 8 (4.7%) | 10 (9.8%) | 5 (8.1%) | 5 (5.8%) | 3 (12.5%) |
| Adjuvant Tx | ||||||
| Number of pts | 244 (54.6%) | 77 (44.8%) | 57 (55.9%) | 38 (61.3%) | 57 (65.5%) | 15 (62.5%) |
| Radio/chemotherapy* | ||||||
| Radiotherapy only | 206 (84.4%) | 74 (96.1%) | 48 (84.2%) | 32 (84.2%) | 40 (70.2%) | 12 (80.0%) |
| Chemotherapy only | 5 (2.1%) | 1 (1.3%) | 1 (1.8%) | 0 | 3 (5.3%) | 0 |
| Radio- chemotherapy | 33 (13.5%) | 2 (2.6%) | 8 (14.0%) | 6 (15.8%) | 14 (24.6%) | 3 (20.0%) |
| Radiation field† | ||||||
| Groins +/- vulva | 66 (27.6%) | 26 (34.2%) | 16 (28.6%) | 8 (21.1%) | 14 (25.9%) | 2 (13.3%) |
| Groins and pelvis +/- vulva | 117 (49.0%) | 34 (44.7%) | 31 (55.4%) | 19 (50.0%) | 26 (48.2%) | 7 (46.7%) |
| Pelvis +/- vulva | 12 (5.0%) | 5 (6.6%) | 2 (3.6%) | 2 (5.3%) | 3 (5.6%) | 0 |
| Vulva only | 8 (3.4%) | 5 (6.6%) | 1 (1.8%) | 1 (2.6%) | 0 | 1 (6.7%) |
| Other (vagina) | 2 (0.8%) | 0 | 1 (1.8%) | 1 (2.6%) | 0 | 0 |
| Unknown | 34 (14.2%) | 6 (7.9%) | 5 (8.9%) | 7 (18.4%) | 11 (20.4%) | 5 (33.3%) |
| Median LN metastasis diameter, mm (range) | 20 (1 – 100) | 8 (1 – 70) | 20 (2 – 80) | 30.5 (8 – 100) | 35 (12 – 70) | 29 (29 – 29)‡ |
* All percentages refer to columns. Percentages refer to patients who received adjuvant treatment. LN = lymph node; N+ = node-positive patients; Tx = therapy.
† Percentages refer to patients who received adjuvant (chemo)radiation.
‡ Only one known LN metastasis diameter.